BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36980323)

  • 21. Retrospective analysis of the prognostic value of PD-L1 expression and
    Jiang H; Zhang R; Jiang H; Zhang M; Guo W; Zhang J; Zhou X; Pan W; Zhao S; Li P
    J Cancer; 2020; 11(10):2864-2873. PubMed ID: 32226504
    [No Abstract]   [Full Text] [Related]  

  • 22. The role of
    Wang X; Yang W; Zhou Q; Luo H; Chen W; Yeung SJ; Zhang S; Gan Y; Zeng B; Liu Z; Feng S; Zhang X; Cheng C
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4241-4251. PubMed ID: 35732974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 in Lung Adenocarcinoma: Insights into the Role of
    Cui Y; Li X; Du B; Diao Y; Li Y
    Cancer Manag Res; 2020; 12():6385-6395. PubMed ID: 32801879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma.
    Zhou X; Hu Y; Sun H; Chen R; Huang G; Liu J
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3107-3115. PubMed ID: 37147479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of Mediastinal Tumors Using SUV
    Morita T; Tatsumi M; Ishibashi M; Isohashi K; Kato H; Honda O; Shimosegawa E; Tomiyama N; Hatazawa J
    Asia Ocean J Nucl Med Biol; 2017; 5(1):22-29. PubMed ID: 28840135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Correlations of
    Wang JL; Shi AQ; Fan CC; Wang YZ; Guo GR; Liu JY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Aug; 44(4):628-635. PubMed ID: 36065696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor immunity is related to
    Imai H; Kaira K; Hashimoto K; Nitanda H; Taguchi R; Yanagihara A; Umesaki T; Yamaguchi O; Mouri A; Kawasaki T; Yasuda M; Kobayashi K; Sakaguchi H; Kuji I; Kagamu H
    Cancer Med; 2021 Sep; 10(18):6317-6326. PubMed ID: 34363337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[
    Wu C; Cui Y; Liu J; Ma L; Xiong Y; Gong Y; Zhao Y; Zhang X; Chen S; He Q; Zhang J; Liu M; Fan Y
    Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4054-4066. PubMed ID: 33978830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of
    Kaymak ZA; Karahan N; Erdoğan M; Erdemoğlu E; Zihni İ; Şengül SS
    Mol Imaging Radionucl Ther; 2021 Jun; 30(2):93-100. PubMed ID: 34082509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of Combined Metabolic-Volumetric Indices of (18)F-FDG PET/CT for the Early Prediction of Neoadjuvant Chemotherapy Outcomes in Breast Cancer.
    Im HJ; Kim YK; Kim YI; Lee JJ; Lee WW; Kim SE
    Nucl Med Mol Imaging; 2013 Mar; 47(1):36-43. PubMed ID: 24895506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Value of
    Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
    Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Jreige M; Letovanec I; Chaba K; Renaud S; Rusakiewicz S; Cristina V; Peters S; Krueger T; de Leval L; Kandalaft LE; Nicod-Lalonde M; Romero P; Prior JO; Coukos G; Schaefer N
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1859-1868. PubMed ID: 31214790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of
    Mayoral M; Paredes P; Saco A; Fusté P; Perlaza P; Tapias A; Fernandez-Martinez A; Vidal L; Ordi J; Pavia J; Martinez-Roman S; Lomeña F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):80-86. PubMed ID: 28869177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of
    Li Y; Li Y; Huang Y; Wu X; Yang Z; Wu C; Jiang L
    Ann Nucl Med; 2021 Sep; 35(9):1048-1057. PubMed ID: 34101153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The correlation between PD-L1 expression and metabolic parameters of
    Xu X; Li J; Yang Y; Sang S; Deng S
    Clin Imaging; 2022 Sep; 89():120-127. PubMed ID: 35797878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of metabolic parameters of primary lesions examined by 18F-FDG PET/CT for endometrial cancer in preoperative evaluation.
    Gai QZ; Lv YB; Li GY; Zhang DQ; Gao Z; Fang XH
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2493-2502. PubMed ID: 33829435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between PD-L1 expression and
    Chen R; Chen Y; Huang G; Liu J
    Aging (Albany NY); 2019 Dec; 11(24):12270-12277. PubMed ID: 31848322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer.
    Miccò M; Vargas HA; Burger IA; Kollmeier MA; Goldman DA; Park KJ; Abu-Rustum NR; Hricak H; Sala E
    Eur J Radiol; 2014 Jul; 83(7):1169-1176. PubMed ID: 24767630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of [
    Zhao L; Zhuang Y; Fu K; Chen P; Wang Y; Zhuo J; Liao X; Chen H; Lin Q
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1065-1074. PubMed ID: 31897588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
    Husby JA; Reitan BC; Biermann M; Trovik J; Bjørge L; Magnussen IJ; Salvesen ØO; Salvesen HB; Haldorsen IS
    J Nucl Med; 2015 Aug; 56(8):1191-8. PubMed ID: 26045311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.